drugset
drugset / Trial / NCT00445900

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

NCT00445900 ↗

Phase 2 Completed 22 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Giving thalidomide together with prednisone and cyclophosphamide may lessen symptoms caused by myelofibrosis and myeloid metaplasia. PURPOSE: This phase II trial is studying the side effects and how well giving thalidomide together with prednisone and cyclophosphamide works in treating patients with myelofibrosis and myeloid metaplasia.

Timeline

Start
2004-10
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — Oral
Subject Prednisone Other / unclassified — Oral
Subject Thalidomide Other / unclassified — Oral

Indications

myelofibrosis